Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
214 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Hodgkin Lymphoma - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Hodgkin Lymphoma - Pipeline Review, H2 2014', provides an overview of the Hodgkin Lymphoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hodgkin Lymphoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hodgkin Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hodgkin Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 8 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Hodgkin Lymphoma Overview 11 Therapeutics Development 12 Pipeline Products for Hodgkin Lymphoma - Overview 12 Pipeline Products for Hodgkin Lymphoma - Comparative Analysis 13 Hodgkin Lymphoma - Therapeutics under Development by Companies 14 Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes 17 Hodgkin Lymphoma - Pipeline Products Glance 19 Late Stage Products 19 Clinical Stage Products 20 Early Stage Products 21 Unknown Stage Products 22 Hodgkin Lymphoma - Products under Development by Companies 23 Hodgkin Lymphoma - Products under Investigation by Universities/Institutes 24 Hodgkin Lymphoma - Companies Involved in Therapeutics Development 25 Bristol-Myers Squibb Company 25 Johnson & Johnson 26 Seattle Genetics, Inc. 27 Merck & Co., Inc. 28 Gamida Cell Ltd. 29 Millennium Pharmaceuticals, Inc. 30 Novartis AG 31 Ono Pharmaceutical Co., Ltd. 32 Sigma-Tau S.p.A. 33 Incyte Corporation 34 4SC AG 35 Dynavax Technologies Corporation 36 Spectrum Pharmaceuticals, Inc. 37 Affimed Therapeutics AG 38 Actinium Pharmaceuticals, Inc. 39 Philogen S.p.A. 40 Constellation Pharmaceuticals, Inc. 41 Stemline Therapeutics, Inc. 42 Syndax Pharmaceuticals, Inc. 43 Acetylon Pharmaceuticals, Inc. 44 Rhizen Pharmaceuticals SA 45 Immune Pharmaceuticals, Inc. 46 Hodgkin Lymphoma - Therapeutics Assessment 47 Assessment by Monotherapy Products 47 Assessment by Target 48 Assessment by Mechanism of Action 52 Assessment by Route of Administration 56 Assessment by Molecule Type 58 Drug Profiles 61 procarbazine hydrochloride - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 panobinostat - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 StemEx - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 brentuximab vedotin - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 entinostat - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 ixazomib citrate - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 MK-2206 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 brentuximab vedotin - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 resminostat - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 ruxolitinib phosphate - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 AFM-13 - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 nivolumab - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 Anti-Tac(Fv)-PE38 Immunotoxin - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 radretumab - Drug Profile 104 Product Description 104 Mechanism of Action 104 R&D Progress 104 Iomab-B - Drug Profile 106 Product Description 106 Mechanism of Action 106 R&D Progress 106 ricolinostat - Drug Profile 108 Product Description 108 Mechanism of Action 108 R&D Progress 108 Ferritarg - Drug Profile 110 Product Description 110 Mechanism of Action 110 R&D Progress 110 JNJ-40346527 - Drug Profile 111 Product Description 111 Mechanism of Action 111 R&D Progress 111 Minor Histocompatibility Antigen - Drug Profile 112 Product Description 112 Mechanism of Action 112 R&D Progress 112 pevonedistat hydrochloride - Drug Profile 113 Product Description 113 Mechanism of Action 113 R&D Progress 113 MDX-1401 - Drug Profile 115 Product Description 115 Mechanism of Action 115 R&D Progress 115 vinorelbine tartrate liposomal - Drug Profile 116 Product Description 116 Mechanism of Action 116 R&D Progress 116 SD-101 - Drug Profile 118 Product Description 118 Mechanism of Action 118 R&D Progress 118 Cell Therapy for Oncology and Infectious Disease - Drug Profile 120 Product Description 120 Mechanism of Action 120 R&D Progress 120 NSC-678515 - Drug Profile 122 Product Description 122 Mechanism of Action 122 R&D Progress 122 Cell Therapy to Inhibit CD30 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile 123 Product Description 123 Mechanism of Action 123 R&D Progress 123 Cell Therapy 3 for Oncology - Drug Profile 124 Product Description 124 Mechanism of Action 124 R&D Progress 124 LMP-400 - Drug Profile 125 Product Description 125 Mechanism of Action 125 R&D Progress 125 LMP-776 - Drug Profile 127 Product Description 127 Mechanism of Action 127 R&D Progress 127 Cell Therapy 2 for Oncology and Infectious Disease - Drug Profile 128 Product Description 128 Mechanism of Action 128 R&D Progress 128 pembrolizumab - Drug Profile 129 Product Description 129 Mechanism of Action 129 R&D Progress 129 TGR-1202 - Drug Profile 131 Product Description 131 Mechanism of Action 131 R&D Progress 131 Cell Therapy for Oncology - Drug Profile 132 Product Description 132 Mechanism of Action 132 R&D Progress 132 INCB-047986 - Drug Profile 133 Product Description 133 Mechanism of Action 133 R&D Progress 133 CPI-0610 - Drug Profile 134 Product Description 134 Mechanism of Action 134 R&D Progress 134 Cell Therapy for Oncology and Infectious Diseases - Drug Profile 135 Product Description 135 Mechanism of Action 135 R&D Progress 135 Monoclonal Antibody to Inhibit CD47 for Metastatic Solid Tumors - Drug Profile 136 Product Description 136 Mechanism of Action 136 R&D Progress 136 SL-101 - Drug Profile 137 Product Description 137 Mechanism of Action 137 R&D Progress 137 Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies - Drug Profile 138 Product Description 138 Mechanism of Action 138 R&D Progress 138 Ferritizumab - Drug Profile 139 Product Description 139 Mechanism of Action 139 R&D Progress 139 Hodgkin Lymphoma - Recent Pipeline Updates 140 Hodgkin Lymphoma - Dormant Projects 199 Hodgkin Lymphoma - Discontinued Products 200 Hodgkin Lymphoma - Product Development Milestones 201 Featured News & Press Releases 201 May 14, 2014: Investigational PD-1 Immune Checkpoint Inhibitor Nivolumab Receives U.S. FDA Breakthrough Therapy Designation for Hodgkin Lymphoma 201 Apr 10, 2014: Affimed Highlights Further Data on AFM13, a Bispecific CD30/CD16A TandAb in Development to Treat Hodgkin Lymphoma, at the 2014 AACR Annual Meeting 201 Apr 07, 2014: TG Therapeutics Announces Preclinical Poster Presentations for TGR-1202 at AACR 2014 202 Feb 27, 2014: Seattle Genetics Highlights ADCETRIS Clinical Data at the 2014 Bone Marrow Transplant Tandem Meetings 203 Jan 17, 2014: Seattle Genetics Announces ADCETRIS Approval in Japan for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma 204 Dec 05, 2013: TG Therapeutics Announces Poster Presentations for TGR-1202 at the Upcoming 55th American Society of Hematology Meeting 205 Oct 11, 2013: Seattle Genetics Highlights ADCETRIS (Brentuximab Vedotin) Clinical Data in the Frontline Setting at the International Symposium on Hodgkin Lymphoma 206 Sep 16, 2013: Affimed Therapeutics and The Leukemia & Lymphoma Society Partner to Advance AFM13 in a Phase 2 Trial for Refractory and/or Relapsed Hodgkin Lymphoma Patients 208 Jun 24, 2013: Affimed Reports Phase I Clinical Data For Its Immunotherapy AFM13 In Relapsing/Refractory Hodgkin Lymphoma Patients 209 Jun 24, 2013: Infinity Pharma Reports Phase I Data Showing Encouraging Clinical Activity Of IPI-145 Across Broad Range Of Blood Cancers At 12th ICML 210 Appendix 213 Methodology 213 Coverage 213 Secondary Research 213 Primary Research 213 Expert Panel Validation 213 Contact Us 214 Disclaimer 214
List of Tables Number of Products under Development for Hodgkin Lymphoma, H2 2014 12 Number of Products under Development for Hodgkin Lymphoma - Comparative Analysis, H2 2014 13 Number of Products under Development by Companies, H2 2014 15 Number of Products under Development by Companies, H2 2014 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H2 2014 18 Comparative Analysis by Late Stage Development, H2 2014 19 Comparative Analysis by Clinical Stage Development, H2 2014 20 Comparative Analysis by Early Stage Development, H2 2014 21 Comparative Analysis by Unknown Stage Development, H2 2014 22 Products under Development by Companies, H2 2014 23 Products under Investigation by Universities/Institutes, H2 2014 24 Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2014 25 Hodgkin Lymphoma - Pipeline by Johnson & Johnson., H2 2014 26 Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2014 27 Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H2 2014 28 Hodgkin Lymphoma - Pipeline by Gamida Cell Ltd., H2 2014 29 Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 30 Hodgkin Lymphoma - Pipeline by Novartis AG, H2 2014 31 Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 32 Hodgkin Lymphoma - Pipeline by Sigma-Tau S.p.A., H2 2014 33 Hodgkin Lymphoma - Pipeline by Incyte Corporation, H2 2014 34 Hodgkin Lymphoma - Pipeline by 4SC AG, H2 2014 35 Hodgkin Lymphoma - Pipeline by Dynavax Technologies Corporation, H2 2014 36 Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2014 37 Hodgkin Lymphoma - Pipeline by Affimed Therapeutics AG, H2 2014 38 Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H2 2014 39 Hodgkin Lymphoma - Pipeline by Philogen S.p.A., H2 2014 40 Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H2 2014 41 Hodgkin Lymphoma - Pipeline by Stemline Therapeutics, Inc., H2 2014 42 Hodgkin Lymphoma - Pipeline by Syndax Pharmaceuticals, Inc., H2 2014 43 Hodgkin Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2014 44 Hodgkin Lymphoma - Pipeline by Rhizen Pharmaceuticals SA, H2 2014 45 Hodgkin Lymphoma - Pipeline by Immune Pharmaceuticals, Inc., H2 2014 46 Assessment by Monotherapy Products, H2 2014 47 Number of Products by Stage and Target, H2 2014 50 Number of Products by Stage and Mechanism of Action, H2 2014 54 Number of Products by Stage and Route of Administration, H2 2014 57 Number of Products by Stage and Molecule Type, H2 2014 60 Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H2 2014 140 Hodgkin Lymphoma - Dormant Projects, H2 2014 199 Hodgkin Lymphoma - Discontinued Products, H2 2014 200
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
